A COMPARISON HIGH- DOSE VERSUS STANDARD- DOSE CYTOSINE ARABINOSIDE IN PATIENTS WITH ACUTE MYELIOD LEUKEMIA IN POSTREMISSION PHASE:

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

REZVANI H.; ATARIAN H.

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: Researcher Bulletin of Medical Sciences Year:2005 | Volume:9 | Issue:6 (42) Page(s): 317-322

Download Full-Text

Persian Verion

View:

2,774

Download:

Cites:

Information Journal Paper

Title

A COMPARISON HIGH- DOSE VERSUS STANDARD- DOSE CYTOSINE ARABINOSIDE IN PATIENTS WITH ACUTE MYELIOD LEUKEMIA IN POSTREMISSION PHASE:

Author(s)

REZVANI H. | ATARIAN H. | Issue Writer Certificate

Keywords

ACUTE MYELIODQ3

CONSOLIDATION THERAPYQ4

HDACQ4

Abstract

Background: Theres a trend toward, using high dose cytarabine as a complementory regimen in post remission phase patients. the use of this regimen in different studies and its lack of use in iranian clinics. made us to design this study to compare the results of high dose cytarabine regimen versus standard high grade dose cytarabine regimen. Materials and Methods: A randomized controlled trial was conducted on 39 patients with AML.Patients with de-novo AML remission with received induction 7+3 regimen. Complete responders to induction therapy were randomized for post remission therapy between HDAC 3 gr/m for 4 days or 7+3 regimen with cytarabin 200 mg/m for 7 days and Dounorobicin at 45 mg/mld for 3 days. Patients with AML (M3) secondary AML or positive myelodysplastic history were excluded. The AML diagnosis was made by aspiration biopsy of the bone marrow and if 50% cellularity and more than 30% myeloblasts were detected in the samples the therapy would have started. Results: 19 out of 39 patients received HDAC and 20 standard 7+3 regimens. With a median follow-up of 36 months there was not significant difference in overall between HDAC and 7+3 regimen. The Survival rate at 24 months was 10% (HDAC) versus 23% (7+3). Disease free Survival (DFS) was 11 months (HDAC) versus 14 months (7+3) and median survival was 14 months (HDAC) versus 19.8 months (7+3).no significant difference between the two groups was detected. Post remission therapy was not associated with a significantly increased risk of hematologic, ocular, hepatic and neurologic toxicity.Conclusion: Although limited, current experience suggests that HDAC regimen maybe a feasible and safe CONSOLIDATION THERAPY without significant toxicity. This study did not demonstrate an improvement in survival for HDAC regimen, however, further studies is needed and recommended.

Cites

No record.

References

No record.

Cite

APA: Copy

REZVANI, H., & ATARIAN, H.. (2005). A COMPARISON HIGH- DOSE VERSUS STANDARD- DOSE CYTOSINE ARABINOSIDE IN PATIENTS WITH ACUTE MYELIOD LEUKEMIA IN POSTREMISSION PHASE:. RESEARCHER BULLETIN OF MEDICAL SCIENCES (PEJOUHANDEH), 9(6 (42)), 317-322. SID. https://sid.ir/paper/18206/en

Vancouver: Copy

REZVANI H., ATARIAN H.. A COMPARISON HIGH- DOSE VERSUS STANDARD- DOSE CYTOSINE ARABINOSIDE IN PATIENTS WITH ACUTE MYELIOD LEUKEMIA IN POSTREMISSION PHASE:. RESEARCHER BULLETIN OF MEDICAL SCIENCES (PEJOUHANDEH)[Internet]. 2005;9(6 (42)):317-322. Available from: https://sid.ir/paper/18206/en

IEEE: Copy

H. REZVANI, and H. ATARIAN, “A COMPARISON HIGH- DOSE VERSUS STANDARD- DOSE CYTOSINE ARABINOSIDE IN PATIENTS WITH ACUTE MYELIOD LEUKEMIA IN POSTREMISSION PHASE:,” RESEARCHER BULLETIN OF MEDICAL SCIENCES (PEJOUHANDEH), vol. 9, no. 6 (42), pp. 317–322, 2005, [Online]. Available: https://sid.ir/paper/18206/en

Related Journal Papers